Study Selection
Eligible studies had to be 1) original investigations published in a peer-reviewed journal before November 1, 2022; 2) include human patients over 18 years old; 3) report an intervention as prophylaxis or treatment for ototoxicity induced by any chemotherapy agent; 4) be published in English; 5) use an experimental or quasi-experimental research design, and 6) report treatment outcomes, either their safety or efficacy. Ototoxicity induced by chemotherapy was considered as hearing loss, tinnitus, or vestibular disturbances after chemotherapy treatment. Gray literature, editorials, commentaries, case series with ten or fewer patients, case studies, and protocols were excluded from the review.